# A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC

> **NCT03876925** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Renal Cell Cancer Metastatic

## Interventions

- **DRUG:** CT053PTSA

## Key facts

- **NCT ID:** NCT03876925
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-25
- **Primary completion:** 2020-03-01
- **Final completion:** 2020-05-12
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The effect of CT053PTSA in preciously treated patients with advanced and metastatic RCC is not as good as pre-expected
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03876925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03876925, "A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03876925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*